Summit Therapeutics (SMMT) Cash from Financing Activities (2017 - 2026)

Summit Therapeutics (SMMT) has 10 years of Cash from Financing Activities data on file, last reported at $231.1 million in Q2 2026.

• Quarterly Cash from Financing Activities rose 10299.55% year-over-year to $231.1 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $842.5 million (up 342.43% YoY) and the FY2025 annual result came in at $617.5 million, up 61.99% from the prior year.
• Cash from Financing Activities grew to $231.1 million in Q2 2026, from $3.8 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $573.8 million in Q4 2025 to a low of -$23.6 million in Q4 2024.
• A 5-year average of $114.1 million and a median of $25.2 million in 2022 frame the typical range for Cash from Financing Activities.
• The widest YoY moves for Cash from Financing Activities: up 250365.0% in 2024, down 477.67% in 2024.
• Tracing SMMT's Cash from Financing Activities over 5 years: stood at $520.1 million in 2022, then tumbled by 98.8% to $6.3 million in 2023, then tumbled by 477.67% to -$23.6 million in 2024, then surged by 2530.21% to $573.8 million in 2025, then sank by 59.73% to $231.1 million in 2026.
• The last three Cash from Financing Activities figures came in at $231.1 million (Q2 2026), $3.8 million (Q1 2026), and $573.8 million (Q4 2025), per Business Quant data.